VolitionRx (NYSE:VNRX) Announces Earnings Results

VolitionRx (NYSE:VNRX) posted its earnings results on Monday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports. VolitionRx had a negative return on equity of 7,185.73% and a negative net margin of 4,557.29%. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.50 million.

VolitionRx Price Performance

VolitionRx stock opened at $0.75 on Wednesday. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 0.56. The stock has a 50 day moving average of $1.00 and a 200-day moving average of $0.87. VolitionRx has a 52 week low of $0.55 and a 52 week high of $2.10.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Vanguard Group Inc. grew its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 16.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 629,639 shares of the company’s stock after buying an additional 87,195 shares during the quarter. Vanguard Group Inc. owned 0.80% of VolitionRx worth $451,000 as of its most recent SEC filing. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.